EU Extends Indication of Bosentan to Pulmonary Arterial Hypertension WHO FC II
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




EU Extends Indication of Bosentan to Pulmonary Arterial Hypertension WHO FC II

NEW YORK -- August 6, 2008 -- The European Union (EU) has approved bosentan (Tracleer) for the treatment of patients with mildly symptomatic pulmonary arterial hypertension (PAH World Health Organization [WHO] functional class [FC] II).

The approval is based on the results from the Endothelin Antagonist Trial in Mildly Symptomatic PAH Patients (EARLY).

The randomised, double-blind, placebo-controlled study of 185 patients showed that pulmonary vascular resistance improved significantly, with a reduction of 22.6% (P < .0001) after 6 months compared with placebo.

A 77% risk reduction in time to clinical worsening (P = .011) was seen after 6 months compared with placebo. Patients receiving bosentan had a lower incidence of worsening functional class (3.4%) compared with placebo (13.2%).

The safety and tolerability profile of bosentan in the EARLY study was consistent with that observed in previous placebo-controlled clinical trials.

SOURCE: Actelion Ltd.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities